It may look good on paper, but the 60% upswing in Perigrine Pharmaceuticals (PPHM +50%) this...


It may look good on paper, but the 60% upswing in Perigrine Pharmaceuticals (PPHM +50%) this morning is a paltry move compared to yesterdays 75% cratering the shares took after reporting that previously released results from a midstage cancer drug study aren't reliable because of a third-party error. The big relative move off the bottom is largely a "dead cat bounce" when you consider that it still remains down 67% from Friday's close.

From other sites
Comments (2)
  • pat45
    , contributor
    Comments (449) | Send Message
     
    Yes but pphm still up 70% from before disputed data results released
    25 Sep 2012, 12:17 PM Reply Like
  • Niners 4 Life!
    , contributor
    Comments (502) | Send Message
     
    Before disputed data results were reported, stock was over $5. Crack kills, bro!
    25 Sep 2012, 12:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs